BofA raised the firm’s price target on Akero Therapeutics (AKRO) to $35 from $30 and keeps a Neutral rating on the shares after updating the firm’s model for the “quiet” third quarter. Material updates were “admittedly light,” but the firm thought Akero’s Q3 update was “positive overall,” the firm stated. The firm now forecasts 2025 EPS of ($4.57), versus ($4.36) previously, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO: